Novavax’s stock remained roughly flat over the last ten trading days (two weeks), compared to the broader market (S&P500) which rose about 1%.A change of -9% or more over five trading days has a 15% event probability, which has occurred 373 times out of 2,516 in the last ten years.Novavax’s stock declined 9% over a five day trading period ending, compared to the broader market (S&P500) which rose by 0.9%.and U.K, it could potentially be used as a booster in other markets.įive Days: NVAX -9%, vs. will likely miss out on initial booster sales in markets such as the U.S. While Novavax - which is in the process of wrapping up its filing for emergency use in the U.S. ![]() That being said, Covid-19 vaccine demand could hold up as governments worldwide look to protect populations against waning immunity from initial doses. FDA recently granted emergency use authorization for oral Covid therapeutics from Merck and Pfizer last week, further reducing concerns about the impact of the recent virus surge. While there has actually been some positive news for Novavax, which indicated that its Covid-19 vaccine showed positive results against the omicron variant of the novel coronavirus, there have been separate studies done in South Africa and the U.K, which indicate that the variant likely isn’t as concerning as initially feared. Now Novavax stock has been particularly badly hit, given that it has yet to deliver its vaccine commercially in the U.S., with regulatory approval only looking likely in the coming months.Ĭovid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) declined by about 9% over the last week (five trading days), compared to the S&P 500 which remains up by about 1% over the same period. For instance, Moderna stock and BioNTech stock are down by almost 20% and 27% year-to-date, respectively. Moreover, therapeutic options for Covid-19 are improving, with the new virus variant also appearing to result in a much lower rate of severe disease, potentially dampening the incentive for people to get booster doses. ![]() With the big initial inoculation drive of the early pandemic now done, it’s looking likely that vaccine demand will remain flat or possibly decline in 2022. Covid-19 daily cases have been surging (over 800,000 over the last week), investors have generally been souring on vaccine stocks for a couple of reasons. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty ImagesĬovid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) has declined by almost 31% thus far in 2022, considerably underperforming the S&P 500, which is down by about -4.5% over the same period. coronavirus vaccine seen in front of Novavax US vaccine development company logo. UKRAINE - 4: In this photo illustration a medical syringe and a vial depicting fake.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |